If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection has been the subject of extensive research. Building on a long tradition of drug safety evaluation, this page summarizes current studies and reports to help you understand the evidence behind PML risk, who is most vulnerable, and how monitoring can reduce harm.
Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. The drug's prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri treatment creates a state of increased susceptibility even in patients without other immune deficiencies. The clinical presentation of PML involves progressive neurological deficits that vary depending on the location of brain lesions. Common symptoms include cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. The disease course is often devastating, with most patients experiencing severe disability or death. Tysabri's mechanism of action involves binding to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial for controlling multiple sclerosis relapses. However, this same mechanism impairs immune surveillance in the brain, allowing latent JCV to reactivate and cause PML. The drug does not directly kill cells or cause mutations; rather, it creates an environment where the virus can replicate unchecked.
Three established risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. The risk increases with cumulative exposure, with most cases occurring after 24 or more infusions. Prior immunosuppressant use further elevates risk by compounding immune suppression. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These trial data established the causal link between Tysabri and PML, leading to the boxed warning and restricted distribution program. The timeline between Tysabri exposure and documented harm varies. PML can develop after as few as eight doses or after several years of treatment. The risk appears to increase with longer duration, particularly beyond two years. Once PML develops, symptoms progress rapidly over weeks to months. Early detection is critical because withholding Tysabri immediately at the first sign or symptom suggestive of PML can improve outcomes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The adequacy of warnings regarding Tysabri and PML is addressed through multiple regulatory mechanisms. The boxed warning clearly states that Tysabri increases PML risk and that the infection usually leads to death or severe disability. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold dosing immediately if such symptoms appear. The drug is available only through the TOUCH Prescribing Program, a restricted distribution program designed to ensure patients are informed of risks and monitored appropriately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For affected patients, causation considerations involve assessing whether PML developed as a direct consequence of Tysabri treatment. The known risk factors—anti-JCV antibody status, treatment duration, and prior immunosuppressant use—help establish the likelihood that Tysabri contributed to the disease. Patients who develop PML while on Tysabri typically have no other identifiable cause of immunosuppression, supporting a causal relationship. The drug's prescribing information explicitly states that Tysabri increases PML risk, and clinical trial data confirm that PML occurred in treated patients but not in untreated controls. When initiating and continuing treatment with Tysabri, physicians must consider whether the expected benefit is sufficient to offset the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This risk-benefit analysis is particularly important for patients with multiple sclerosis who have failed other therapies, as the drug's efficacy in reducing relapses must be weighed against the potential for a fatal or disabling brain infection. The TOUCH program requires documented discussion of PML risk before each infusion, ensuring ongoing informed consent. In summary, the evidence establishes a clear causal relationship between Tysabri and PML. The drug's mechanism of action impairs immune surveillance in the brain, allowing JCV reactivation. Clinical trial data and post-marketing surveillance confirm increased PML incidence in treated patients. Risk factors are well-characterized, and regulatory warnings are comprehensive. Patients and healthcare providers must remain vigilant for early symptoms and follow monitoring protocols to mitigate harm.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Request archival records or inquire about member-exclusive transition and benefit programs.
Yes, Tysabri (natalizumab) increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The drug's prescribing information includes a boxed warning stating that Tysabri increases PML risk, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with cumulative exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early detection is critical because withholding Tysabri immediately at the first sign or symptom suggestive of PML can improve outcomes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.